FDA Brief

Warning letters Drugs

FDA warning letter to

Jagsonpal Pharmaceuticals Limited

High riskIssued Feb 5, 2025Posted Feb 18, 2025Center for Drug Evaluation and Research (CDER)

Jagsonpal Pharmaceuticals cited for API CGMP and listing failures after Indian inspection, leading to US import alert.

What happened

FDA inspected Jagsonpal's registered facility in Bhiwadi, Rajasthan, India on March 20, March 27 and April 3, 2024, after being refused entry at that address on March 15, 2024 and later given only limited access to documents. Investigators found the company's quality unit did not ensure that its contract manufacturer made the API according to CGMP, and that the drug was made at a facility not registered with FDA and was listed under the wrong manufacturer. FDA placed products from the firm on Import Alert 66-40 on January 17, 2025.

What FDA found

  1. The quality unit failed to make sure the API made at its contract manufacturer met CGMP, including that process validation was done, master production instructions were complete, and test methods were verified.

    FD&C Act section 501(a)(2)(B), 21 U.S.C. 351(a)(2)(B)
  2. FDA was refused entry at the registered address on March 15, 2024, and on March 20, 2024 complete analytical data, equipment logbooks and change control documents were not provided when asked for.

    FD&C Act section 501(j)
  3. The company registered itself as the FDA-registered establishment even though the drug was made at a contract facility that is not registered with FDA as a drug manufacturer.

    FD&C Act section 510, 21 U.S.C. 360; 21 CFR Part 207
  4. The drug listing names Jagsonpal as the manufacturer instead of the contract manufacturer that actually made the drug.

    21 CFR 207.49(a)(12)
  5. The drug was made at an unregistered facility and was not listed by that facility, so it is misbranded.

    21 CFR 207.41(a); FD&C Act section 502(o), 21 U.S.C. 352(o)

What FDA wants

FDA tells the company to send a comprehensive assessment and remediation plan for quality unit oversight, including qualification of its contract manufacturers, and to confirm that its contract manufacturer is registered with FDA. The written reply is due within 15 working days.

Who should pay attention

  • US brands and distributors named as manufacturer on import records for products made by contractors
  • companies buying APIs made under contract manufacturing arrangements in India
  • quality teams that manage CMO quality agreements, process validation and drug listing data

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk